Stoll Matthew Laurence, Vaid Yoginder Nath, Guleria Saurabh, Beukelman Timothy, Waite Peter Daniel, Cron Randy Quentin
Form the Department of Pediatrics, and Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham; Department of Radiology, Children's of Alabama, Birmingham, Alabama, USA.M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, University of Alabama at Birmingham; Y.N. Vaid, MD; S. Guleria, MD, Department of Radiology, Children's of Alabama; T. Beukelman, MD, MSCE, Department of Pediatrics, University of Alabama at Birmingham; P.D. Waite, MPH, DDS, MD, Department of Oral and Maxillofacial Surgery, University of Alabama at Birmingham; R.Q. Cron, MD, PhD, Department of Pediatrics, University of Alabama at Birmingham.
J Rheumatol. 2015 Nov;42(11):2155-9. doi: 10.3899/jrheum.150308. Epub 2015 Sep 1.
To evaluate the involvement of intraarticular (IA) infliximab (IFX) in the management of temporomandibular joint (TMJ) arthritis associated with juvenile idiopathic arthritis (JIA) that is refractory to systemic treatment and IA corticosteroid therapy.
Ours was a retrospective study of children with JIA who received IA IFX into the TMJ. The effectiveness of treatment on the progression of acute and chronic changes was assessed by a quantitative magnetic resonance imaging scoring system.
Median acute and chronic scores worsened by 0.25 and 0.75, respectively. In multivariate analysis, worsening acute scores and passage of time predicted worsening of the chronic scores.
IA IFX allowed for progression of refractory TMJ arthritis in most but not all children with JIA.
评估关节腔内注射英夫利昔单抗（IFX）在治疗与幼年特发性关节炎（JIA）相关的颞下颌关节（TMJ）关节炎中的作用，该关节炎对全身治疗和关节腔内皮质类固醇治疗无效。
我们对接受关节腔内注射IFX治疗颞下颌关节的JIA患儿进行了一项回顾性研究。通过定量磁共振成像评分系统评估治疗对急性和慢性变化进展的有效性。
急性和慢性评分中位数分别恶化了0.25和0.75。在多变量分析中，急性评分恶化和时间推移预示着慢性评分会恶化。
关节腔内注射IFX使大多数但并非所有JIA患儿的难治性颞下颌关节炎病情进展。
